| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
19,370,000 |
| Market
Cap: |
776.74(K) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.0401 - $1.8 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aravive is a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of diseases, including cancer and fibrosis. Co.'s primary product candidate, batiraxcept, is a decoy protein that targets the GAS6-AXL signaling pathway. By capturing serum GAS6, batiraxcept starves the AXL pathway of its signal, potentially halting the biological programming that promotes disease progression. AXL receptor signaling plays a role in multiple types of malignancies by promoting metastasis, cancer cell survival, resistance to treatments, and immune suppression.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Shepard Jay |
President and CEO |
• • – |
2015-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
96,000 |
96,000 |
|
- |
|
| Westberg Paul |
Sr. VP, Business Development |
• – – |
2015-05-04 |
4 |
AS |
$17.47 |
$41,929 |
D/D |
(2,400) |
22,487 |
|
- |
|
| Westberg Paul |
Sr. VP, Business Development |
• – – |
2015-05-04 |
4 |
OE |
$1.27 |
$3,036 |
D/D |
2,400 |
24,887 |
|
- |
|
| Cleland Jeffrey L |
President and CEO |
• • – |
2015-04-14 |
4 |
AS |
$20.13 |
$161,040 |
D/D |
(8,000) |
121,548 |
|
- |
|
| Westberg Paul |
Sr. VP, Business Development |
• – – |
2015-04-06 |
4 |
AS |
$17.49 |
$41,972 |
D/D |
(2,400) |
22,487 |
|
- |
|
| Westberg Paul |
Sr. VP, Business Development |
• – – |
2015-04-06 |
4 |
OE |
$1.27 |
$3,036 |
D/D |
2,400 |
24,887 |
|
- |
|
| Cleland Jeffrey L |
President and CEO |
• • – |
2015-03-23 |
4 |
AS |
$20.26 |
$81,029 |
D/D |
(4,000) |
93,432 |
|
- |
|
| Cleland Jeffrey L |
President and CEO |
• • – |
2015-03-20 |
4 |
AS |
$20.07 |
$14,850 |
D/D |
(740) |
97,432 |
|
- |
|
| Cleland Jeffrey L |
President and CEO |
• • – |
2015-03-19 |
4 |
AS |
$20.01 |
$26,311 |
D/D |
(1,315) |
98,172 |
|
- |
|
| Cleland Jeffrey L |
President and CEO |
• • – |
2015-03-18 |
4 |
AS |
$20.03 |
$22,515 |
D/D |
(1,124) |
99,487 |
|
- |
|
| Cleland Jeffrey L |
President and CEO |
• • – |
2015-03-17 |
4 |
AS |
$20.09 |
$14,827 |
D/D |
(738) |
100,611 |
|
- |
|
| Cleland Jeffrey L |
President and CEO |
• • – |
2015-03-16 |
4 |
AS |
$20.01 |
$1,661 |
D/D |
(83) |
101,349 |
|
- |
|
| Cleland Jeffrey L |
President and CEO |
• • – |
2015-03-10 |
4 |
AS |
$20.30 |
$51,502 |
D/D |
(2,537) |
101,432 |
|
- |
|
| Cleland Jeffrey L |
President and CEO |
• • – |
2015-03-09 |
4 |
AS |
$20.10 |
$29,411 |
D/D |
(1,463) |
103,969 |
|
- |
|
| Cleland Jeffrey L |
President and CEO |
• • – |
2015-03-03 |
4 |
AS |
$20.07 |
$22,658 |
D/D |
(1,129) |
105,432 |
|
- |
|
| Westberg Paul |
Sr. VP, Business Development |
• – – |
2015-03-03 |
4 |
AS |
$20.03 |
$48,070 |
D/D |
(2,400) |
22,487 |
|
- |
|
| Westberg Paul |
Sr. VP, Business Development |
• – – |
2015-03-03 |
4 |
OE |
$1.27 |
$3,036 |
D/D |
2,400 |
24,887 |
|
- |
|
| Cleland Jeffrey L |
President and CEO |
• • – |
2015-03-02 |
4 |
AS |
$20.11 |
$57,748 |
D/D |
(2,871) |
106,561 |
|
- |
|
| Cleland Jeffrey L |
President and CEO |
• • – |
2015-02-25 |
4 |
AS |
$20.25 |
$161,977 |
D/D |
(8,000) |
109,432 |
|
- |
|
| Westberg Paul |
Sr. VP, Business Development |
• – – |
2015-02-03 |
4 |
AS |
$17.34 |
$86,985 |
D/D |
(5,000) |
22,487 |
|
- |
|
| Westberg Paul |
Sr. VP, Business Development |
• – – |
2015-02-03 |
4 |
OE |
$1.27 |
$6,325 |
D/D |
5,000 |
27,487 |
|
- |
|
| Schiff Dr Drew |
10% Owner |
– – • |
2015-01-27 |
4 |
B |
$17.25 |
$2,501,250 |
I/I |
145,000 |
2,139,568 |
1.5 |
- |
|
| Sun Anthony Y |
Director |
– • – |
2015-01-27 |
4 |
B |
$17.25 |
$2,501,250 |
I/I |
145,000 |
2,139,568 |
2.1 |
- |
|
| Greer R Scott |
Director |
– • – |
2015-01-27 |
4 |
B |
$17.25 |
$94,875 |
D/D |
5,500 |
10,500 |
2.39 |
- |
|
| Advent Life Sciences Fund I Lp |
Affiliate of Director |
– – – |
2015-01-22 |
4 |
B |
$17.25 |
$948,750 |
I/I |
55,000 |
2,271,558 |
0.01 |
- |
|
258 Records found
|
|
Page 9 of 11 |
|
|
